Sanofi Unit Touts 4-Year Data for AYVAKIT
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study of the drug AYVAKIT. The results show a sustained benefit and long-term safety profile for patients with indolent systemic mastocytosis, a rare blood disorder.
Indolent systemic mastocytosis (ISM) is characterized by an overproduction of mast cells, leading to a wide range of debilitating symptoms like skin rashes, gastrointestinal issues, and even anaphylaxis. In approximately 95% of cases, the disease is driven by a specific genetic mutation known as KIT D816V. AYVAKIT (avapritinib) is a targeted therapy designed to potently and selectively inhibit this KIT D816V mutation. By blocking the action of this mutated protein, the drug helps to control the proliferation and activation of mast cells, addressing the underlying cause of the disease. The U.S. Food and Drug Administration (FDA) approved AYVAKIT for adults with indolent systemic mastocytosis in May 2023. This approval was a significant milestone, marking a shift from merely managing symptoms with supportive care to a disease-modifying therapy. The approval was based on the initial results of the double-blind, placebo-controlled PIONEER trial. In that study, AYVAKIT demonstrated a statistically significant and clinically meaningful improvement in patients' total symptom scores compared to a placebo. Prior to its approval for the indolent form, AYVAKIT was greenlit by the FDA in June 2021 for advanced systemic mastocytosis, a more aggressive form of the disease. This earlier approval was supported by data from the EXPLORER and PATHFINDER trials. The latest four-year data from the PIONEER open-label extension study provides crucial long-term insights. It shows that the benefits of AYVAKIT in reducing symptoms and its favorable safety profile are sustained over a prolonged period, supporting its potential for chronic use in this patient population.
